Exploiting replication gaps for cancer therapy

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• BRCA1/BRCA2 (BRCA) mutations are traditionally associated with defects in DNA double-strand break repair.
• Tumors with BRCA mutations are often considered selectively sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis).

Purpose of the Study:

• To challenge the established framework linking BRCAness solely to double-strand break repair defects.
• To explore the shared functions of BRCA proteins and PARP1 in DNA synthesis, specifically on the lagging strand.
• To propose an alternative model for PARPi sensitivity in BRCA-deficient or BRCAness tumors.

Main Methods:

• Investigated the functional overlap between BRCA proteins and PARP1 in DNA replication.
• Analyzed the consequences of BRCA deficiency on lagging strand DNA synthesis.
• Examined the impact of PARPi on cells with BRCA deficiency or "BRCAness".

Main Results:

• BRCA proteins and PARP1 share critical functions in DNA synthesis on the lagging strand.
• BRCA deficiency or "BRCAness" may represent an inherent lagging strand synthesis problem.
• Co-targeting the lagging strand with PARPi in BRCA-deficient contexts leads to a toxic accumulation of replication gaps.

Conclusions:

• BRCAness-associated PARPi sensitivity may arise from targeting shared lagging strand DNA synthesis functions.
• This revised understanding offers a new perspective on the mechanism of action for PARPis in BRCA-mutant and BRCAness tumors.
• The combination of BRCA deficiency and PARPi treatment creates a synthetic lethal interaction through replication stress.